PBYI 10 Year Annualized Return and Average Annual Return

The PBYI 10 year annualized return is -10.79% with dividends reinvested through 05/11/2026. Investors often use annualized return to compare long-term performance because it shows the average yearly compounded return over a full period rather than just the headline total gain.

This page shows PBYI average annual return, total return, start and end dates, and the growth of a hypothetical $10,000 investment with dividends reinvested.

Quick links: Annualized Return Table  |  Performance Chart  |  FAQ
PBYI Average Annual Return Chart 10 Years
Growth of $10,000.00
Without Dividends Reinvested Into PBYI

Also see:
• PBYI stock yearly return 2016
• PBYI stock yearly return 2017
• PBYI stock yearly return 2018
• PBYI stock yearly return 2019
• PBYI stock yearly return 2020
• PBYI stock yearly return 2021
• PBYI stock yearly return 2022
• PBYI stock yearly return 2023
• PBYI stock yearly return 2024
• PBYI stock yearly return 2025
• PBYI YTD return
Average Annual Return Benchmarks
Compare PBYI average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
PBYI Share Performance
PBYI Average Annual Return Table 10 Years
Start date: 05/12/2016
End date: 05/11/2026
Start price/share: $22.36
End price/share: $7.14
Dividends collected/share: $0.00
Total return: -68.07%
PBYI Average Annual Return: -10.79%
Starting investment: $10,000.00
Ending investment: $3,191.53
Years: 10.00


PBYI average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
About Puma Biotechnology Inc
Puma Biotechnology, Inc. is a biopharmaceutical company. Co. is focused on the development and commercialization of products to enhance cancer care. Co.'s lead product is NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4 It also engaged in the development and commercialization of, alisertib. The PBYI average annual return 10 years is shown above.

The Average Annual Return on the PBYI average annual return 10 years page and across the coverage universe of our site, is a measure of the annualized return over the past ten years (or specified start date) for a given investment (up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window to capture long-term trends.

Thus, researching Average Annual Returns is good practice for investors — whether PBYI average annual return 10 years or other benchmarks/peers — and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors by performing the PBYI average annual return calculation with any dividends reinvested as applicable (on ex-dates).
PBYI Current Stock Quote
Quotes delayed 20 minutes

Email EnvelopeFree PBYI Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
Featured Slideshows
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!
Video: Don't Forget Dividends in Average Annual Return!
Average Annual Return Peers
Puma Biotechnology (PBYI) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

PCRX Average Annual Return
PCSA Average Annual Return
PCVX Average Annual Return
PDEX Average Annual Return
PDSB Average Annual Return
PEN Average Annual Return
PEPG Average Annual Return
PETV Average Annual Return
PFE Average Annual Return
PGEN Average Annual Return
More Healthcare companies »
What has the average annual return been for PBYI over the past ten years?
✔️Accepted answer: The ten year PBYI average annual return has been -10.79%.

What start date was used in your PBYI average annual return calculation?
✔️Accepted answer: The start date was 05/12/2016.

What end date was used in your PBYI average annual return calculation?
✔️Accepted answer: The end date was 05/11/2026.

If I had invested $10,000 into PBYI ten years ago, how much would I have today?
✔️Accepted answer: Today, as of 05/11/2026, you would have $3,191.53.

What does that work out to on a total return basis?
✔️Accepted answer: The PBYI ten year total return ending 05/11/2026 works out to -68.07%.


Also see:
• PBYI stock yearly return 2016
• PBYI stock yearly return 2017
• PBYI stock yearly return 2018
• PBYI stock yearly return 2019
• PBYI stock yearly return 2020
• PBYI stock yearly return 2021
• PBYI stock yearly return 2022
• PBYI stock yearly return 2023
• PBYI stock yearly return 2024
• PBYI stock yearly return 2025
• PBYI YTD return
 

PBYI 10 Year Annualized Return & Average Annual Return | www.AverageAnnualReturn.com | Copyright © 2021 - 2026, All Rights Reserved

Nothing in AverageAnnualReturn.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.